- Home
- ARHS vs AGIO Comparison
ARHS vs AGIO Comparison
Compare ARHS & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARHS | AGIO |
|---|---|---|
| Founded | 1986 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ARHS | AGIO |
|---|---|---|
| Price | $7.87 | $28.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | $11.71 | ★ $36.63 |
| AVG Volume (30 Days) | ★ 1.3M | 769.4K |
| Earning Date | 06-02-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $1,379,222,000.00 | $43,011,000.00 |
| Revenue This Year | $7.38 | $103.08 |
| Revenue Next Year | $6.89 | $126.67 |
| P/E Ratio | $16.63 | ★ N/A |
| Revenue Growth | ★ 8.51 | N/A |
| 52 Week Low | $6.61 | $22.24 |
| 52 Week High | $12.97 | $46.00 |
Technical Indicators
Market Signals| Indicator | ARHS | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 33.20 | 47.58 |
| Support Level | N/A | $26.40 |
| Resistance Level | $9.07 | $29.49 |
| Average True Range (ATR) | 0.65 | 1.28 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 6.76 | 32.07 |
Price Performance
Historical ComparisonAbout ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.